

# FGFR3 fusions dimerize

Grose, RP., Rothfels, K.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

01/04/2024

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

## Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88

This document contains 1 reaction ([see Table of Contents](#))


## FGFR3 fusions dimerize ↗

**Stable identifier:** R-HSA-8853317

**Type:** transition

**Compartments:** plasma membrane

**Diseases:** cancer



Constitutively active fusions of FGFR3 have been identified in glioblastoma, non-small cell lung cancer and bladder cancer, among others (Singh et al, 2012; Williams et al, 2013; Wu et al, 2013; Wang et al, 2014; Capelletti et al, 2014; Yuan et al, 2015; Carneiro et al, 2015; reviewed in Parker et al, 2014). The most prevalent fusion partner is TACC3 (transforming acidic coiled-coil-containing protein 3), a microtubule binding protein with roles in microtubule spindle assembly and chromosome segregation (Singh et al, 2014; Burgess et al, 2015; reviewed in Parker et al, 2014). There are conflicting reports about whether FGFR3 fusions form constitutive dimers, however ligand-independent autophosphorylation and downstream signaling has been demonstrated. FGFR3 fusions promote cellular proliferation and tumorigenesis and appear to escaped miRNA-mediated downregulation (Singh et al, 2012; Williams et al, 2013; Wu et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014).

### Literature references

- Parker, BC., Sun, Y., Granberg, KJ., Zhang, W., Liu, CG., Ji, P. et al. (2013). The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. *J. Clin. Invest.*, 123, 855-65. ↗
- Cavazza, T., Joseph, N., Bayliss, R., Gergely, F., Vernos, I., Burgess, SG. et al. (2015). Aurora-A-Dependent Control of TACC3 Influences the Rate of Mitotic Spindle Assembly. *PLoS Genet.*, 11, e1005345. ↗
- Knowles, MA., Williams, SV., Hurst, CD. (2013). Oncogenic FGFR3 gene fusions in bladder cancer. *Hum. Mol. Genet.*, 22, 795-803. ↗
- Kalyana-Sundaram, S., Chinnaiyan, AM., Wang, R., Tomlins, SA., Ateeq, B., Cao, X. et al. (2013). Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov.*, 3, 636-47. ↗
- Zeng, MS., Yuan, L., Liu, ZH., Lin, ZR., Zhong, Q., Xu, LH. (2014). Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. *Cancer Biol. Ther.*, 15, 1613-21. ↗

### Editions

2016-01-09	Authored, Edited	Rothfels, K.
2016-01-25	Reviewed	Grose, RP.